98%
921
2 minutes
20
Background: The Suvar, Enhancer of zeste, and Trithorax (SET), myeloid-Nervy-DEAF-1 (MYND) domain-containing protein 3 (SMYD3), was reported to be upregulated in various tumors. However, its role in pancreatic cancer progression remains unclear.
Aims: To explore the role of SMYD3 in the pancreatic cancer.
Methods: The expressions of SMYD3, caspase-3, and matrix metallopeptidase-2 (MMP-2) were detected in pancreatic cancer and non-tumor tissues by immunohistochemistry. The CCK-8 and transwell assays were performed to test proliferation, migration, and invasion ability in short hairpin RNA (shRNA-SMYD3) pancreatic cancer cell line SW1190. RT-PCR and Western blot were used to detect the expressions of SMYD3, caspase-3, and MMP-2 in SW1990 cell line and shRNA-SMYD3 SW1990 cell line.
Results: The expressions of SMYD3, caspase-3, and MMP-2 were upregulated in pancreatic cancer. The SMYD3 was positively associated with caspase-3 and MMP-2 expressions in pancreatic cancer tissues. SMYD3, TNM stages, histological differentiation, and lymph node metastasis were identified as an independent prognostic factor. Moreover, interfered SMYD3 expression in SW1990 cell line significantly reduced the cell proliferation, migration, and invasion. RT-PCR and Western blot showed the expression of MMP-2 decreased in shRNA-SMYD3 SW1990 cell line, but no significant change was observed in the caspase-3 expression.
Conclusions: The overexpression of SMYD3 promoted proliferation, migration, and invasion of pancreatic cancer, and SMYD3 may affect the pancreatic cancer progression by regulating MMP-2 rather than caspase-3.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10620-019-05797-y | DOI Listing |
J Clin Oncol
September 2025
University of California San Francisco, San Francisco, CA.
Eur J Gastroenterol Hepatol
September 2025
Background: Prior studies have implicated diabetes as a risk factor for pancreatic cancer, yet the impact of diabetes progression on pancreatic cancer incidence remains unclear. We aim to assess pancreatic cancer risk across different stages of diabetes.
Methods: Employing a predefined search strategy, we conducted a literature review of electronic databases up to 29 February 2024.
J Clin Oncol
September 2025
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore, MD.
Purpose: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX; mFFX) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers.
Patients And Methods: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in or . The primary end point was progression-free survival (PFS) between arms with 0.
PLoS One
September 2025
Department of Gastroenterology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, China.
Objective: To evaluate the burden and trends of digestive system cancers in adolescents and young adults (AYAs) globally between 1990 and 2021.
Methods: Data were extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (1990-2021). We analyzed global, regional, and national disease burdens by calculating the age-standardized incidence (ASIR), mortality (ASMR), and disability-adjusted life years (DALYs) for AYAs.
IEEE Trans Med Imaging
September 2025
Intravoxel Incoherent Motion (IVIM) MRI is a contrast-agent-free microvascular imaging method finding increasing use in biomedicine. However, there is uncertainty in the ability of IVIM-MRI to quantify tissue microvasculature given MRI's limited spatial resolution (mm scale). Nine NRG mice were subcutaneously inoculated with human pancreatic cancer BxPC-3 cells transfected with DsRed, and MR-compatible plastic window chambers were surgically installed in the dorsal skinfold.
View Article and Find Full Text PDF